{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:45:10Z","timestamp":1788410710981,"version":"build-2803163510"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04137-z","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:03:31Z","timestamp":1763809411000},"page":"1549-1569","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Overcoming tumour resistance in cancer immunotherapy through predictive and pharmacodynamic biomarkers"],"prefix":"10.1007","volume":"28","author":[{"given":"Heena","family":"Kansal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Chopra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kranti","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9414-3771","authenticated-orcid":false,"given":"Siddharth","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,22]]},"reference":[{"issue":"3","key":"4137_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4137_CR2","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12032-025-02822-1","volume":"42","author":"MR Zamani","year":"2025","unstructured":"Zamani MR, \u0160\u00e1cha P. Immune checkpoint inhibitors in cancer therapy: what lies beyond monoclonal antibodies? Med Oncol. 2025;42(7):273.","journal-title":"Med Oncol"},{"issue":"1","key":"4137_CR3","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/s12672-024-01638-1","volume":"15","author":"A Fayyaz","year":"2024","unstructured":"Fayyaz A, Haqqi A, Khan R, Irfan M, Khan K, Reiner \u017d, et al. Revolutionizing cancer treatment: the rise of personalized immunotherapies. Discov Oncol. 2024;15(1):756.","journal-title":"Discov Oncol"},{"issue":"12","key":"4137_CR4","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1007\/s12094-020-02372-0","volume":"22","author":"D Kriz","year":"2020","unstructured":"Kriz D, Ansari D, Andersson R. Potential biomarkers for early detection of pancreatic ductal adenocarcinoma. Clin Transl Oncol. 2020;22(12):2170\u20134. https:\/\/doi.org\/10.1007\/s12094-020-02372-0.","journal-title":"Clin Transl Oncol"},{"key":"4137_CR5","doi-asserted-by":"crossref","unstructured":"Liu W, Zhou H, Lai W, Hu C, Xu R, Gu P, Luo M, Zhang R, Li G. The immunosuppressive landscape in tumor microenvironment.\n Immunol Res. 2024;72(4):566\u201382.","DOI":"10.1007\/s12026-024-09483-8"},{"issue":"8","key":"4137_CR6","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865\u201374.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4137_CR7","first-page":"451","volume":"21","author":"X Kong","year":"2024","unstructured":"Kong X, Zhang J, Chen S, Wang X, Xi Q, Shen H, et al. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024;21(6):451\u201372.","journal-title":"Cancer Biol Med"},{"issue":"6382","key":"4137_CR8","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June CH, O\u2019Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361\u20135.","journal-title":"Science"},{"issue":"1","key":"4137_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-023-00372-8","volume":"12","author":"W Ma","year":"2023","unstructured":"Ma W, Xue R, Zhu Z, Farrukh H, Song W, Li T, et al. Increasing cure rates of solid tumors by immune checkpoint inhibitors. Exp Hematol Oncol. 2023;12(1):10.","journal-title":"Exp Hematol Oncol"},{"key":"4137_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1200\/EDBK_159135","volume":"35","author":"CK Anders","year":"2016","unstructured":"Anders CK, Abramson V, Tan T, Dent R. The evolution of triple-negative breast cancer: from biology to novel therapeutics. Am Soc Clin Oncol Educ Book. 2016;35:34.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9","key":"4137_CR11","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","volume":"20","author":"CM Jackson","year":"2019","unstructured":"Jackson CM, Choi J, Lim M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat Immunol. 2019;20(9):1100\u20139.","journal-title":"Nat Immunol"},{"key":"4137_CR12","doi-asserted-by":"crossref","unstructured":"Hanahan D, Michielin O, Pittet MJ. Convergent inducers and effectors of T cell paralysis in the tumour microenvironment. Nat Rev Cancer. 2025;25(1):41\u201358.","DOI":"10.1038\/s41568-024-00761-z"},{"issue":"3","key":"4137_CR13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/jcm12030953","volume":"12","author":"X Wang","year":"2023","unstructured":"Wang X, Collet L, Rediti M, Debien V, De Caluw\u00e9 A, Venet D, et al. Predictive biomarkers for response to immunotherapy in triple negative breast cancer: promises and challenges. J Clin Med. 2023;12(3):953.","journal-title":"J Clin Med"},{"issue":"2","key":"4137_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s12094-019-02273-x","volume":"22","author":"M Majem","year":"2020","unstructured":"Majem M, Garc\u00eda-Mart\u00ednez E, Martinez M, Mu\u00f1oz-Couselo E, Rodriguez-Abreu D, Alvarez R, et al. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clin Transl Oncol. 2020;22(2):213\u201322. https:\/\/doi.org\/10.1007\/s12094-019-02273-x.","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"4137_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s12094-019-02218-4","volume":"22","author":"P Garrido","year":"2020","unstructured":"Garrido P, Conde E, De Castro J, G\u00f3mez-Rom\u00e1n JJ, Felip E, Pijuan L, et al. Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2020;22(7):989\u20131003. https:\/\/doi.org\/10.1007\/s12094-019-02218-4.","journal-title":"Clin Transl Oncol"},{"issue":"6","key":"4137_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, V\u00e9tizou M, Daill\u00e8re R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and-extrinsic factors. Immunity. 2016;44(6):1255\u201369.","journal-title":"Immunity"},{"issue":"4","key":"4137_CR17","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707\u201323.","journal-title":"Cell"},{"key":"4137_CR18","doi-asserted-by":"publisher","first-page":"120562","DOI":"10.1016\/j.biomaterials.2020.120562","volume":"268","author":"S Yang","year":"2021","unstructured":"Yang S, Chen C, Qiu Y, Xu C, Yao J. Paying attention to tumor blood vessels: cancer phototherapy assisted with nano delivery strategies. Biomaterials. 2021;268:120562.","journal-title":"Biomaterials"},{"key":"4137_CR19","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jconrel.2020.08.016","volume":"327","author":"S Adityan","year":"2020","unstructured":"Adityan S, Tran M, Bhavsar C, Wu SY. Nano-therapeutics for modulating the tumour microenvironment: design, development, and clinical translation. J Control Release. 2020;327:512\u201332.","journal-title":"J Control Release"},{"issue":"5","key":"4137_CR20","doi-asserted-by":"publisher","first-page":"188792","DOI":"10.1016\/j.bbcan.2022.188792","volume":"1877","author":"H Salavati","year":"2022","unstructured":"Salavati H, Debbaut C, Pullens P, Ceelen W. Interstitial fluid pressure as an emerging biomarker in solid tumors. Biochim Biophys Acta (BBA)-Rev Cancer. 2022;1877(5):188792.","journal-title":"Biochim Biophys Acta (BBA)-Rev Cancer"},{"key":"4137_CR21","doi-asserted-by":"crossref","unstructured":"Abazari MA, Soltani M, Kashkooli FM. Targeted nano-sized drug delivery to heterogeneous solid tumor microvasculatures: implications for immunoliposomes exhibiting bystander killing effect. Phys Fluids. 2023;35(1):011905.","DOI":"10.1063\/5.0130259"},{"key":"4137_CR22","doi-asserted-by":"publisher","first-page":"1291530","DOI":"10.3389\/fimmu.2023.1291530","volume":"14","author":"C Qian","year":"2023","unstructured":"Qian C, Liu C, Liu W, Zhou R, Zhao L. Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy. Front Immunol. 2023;14:1291530.","journal-title":"Front Immunol"},{"issue":"3","key":"4137_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-025-03954-z","volume":"74","author":"C Lv","year":"2025","unstructured":"Lv C, Chen T, Li J, Shan Y, Zhou H. A comprehensive analysis of molecular characteristics of hot and cold tumor of gastric cancer. Cancer Immunol Immunother. 2025;74(3):1\u20137.","journal-title":"Cancer Immunol Immunother"},{"issue":"14","key":"4137_CR24","doi-asserted-by":"publisher","first-page":"11673","DOI":"10.3390\/ijms241411673","volume":"24","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Wieder T, Mauerer B, Sch\u00e4fer L, Kesselring R, Braum\u00fcller H. T cells in colorectal cancer: unravelling the function of different T cell subsets in the tumor microenvironment. Int J Mol Sci. 2023;24(14):11673.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"4137_CR25","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365.","journal-title":"Theranostics"},{"issue":"3","key":"4137_CR26","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nri.2017.145","volume":"18","author":"Y Huang","year":"2018","unstructured":"Huang Y, Kim BY, Chan CK, Hahn SM, Weissman IL, Jiang W. Improving immune-vascular crosstalk for cancer immunotherapy. Nat Rev Immunol. 2018;18(3):195\u2013203. https:\/\/doi.org\/10.1038\/nri.2017.145.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4137_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Signal Transduct Target Ther. 2024;9(1):274.","journal-title":"Signal Transduct Target Ther"},{"key":"4137_CR28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3389\/fimmu.2019.01078","volume":"10","author":"H Harjunp\u00e4\u00e4","year":"2019","unstructured":"Harjunp\u00e4\u00e4 H, Llort Asens M, Guenther C, Fagerholm SC. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment. Front Immunol. 2019;10:1078.","journal-title":"Front Immunol"},{"key":"4137_CR29","doi-asserted-by":"publisher","first-page":"117177","DOI":"10.1016\/j.biopha.2024.117177","volume":"178","author":"NK Bhol","year":"2024","unstructured":"Bhol NK, Bhanjadeo MM, Singh AK, Dash UC, Ojha RR, Majhi S, et al. The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed Pharmacother. 2024;178:117177.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"4137_CR30","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/bjc.2017.13","volume":"116","author":"LM Schiffmann","year":"2017","unstructured":"Schiffmann LM, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, et al. A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition. Br J Cancer. 2017;116(5):600\u20138. https:\/\/doi.org\/10.1038\/bjc.2017.13.","journal-title":"Br J Cancer"},{"issue":"1","key":"4137_CR31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","volume":"10","author":"X Yu","year":"2024","unstructured":"Yu X, Zhao H, Wang R, Chen Y, Ouyang X, Li W, et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Discov. 2024;10(1):28.","journal-title":"Cell Death Discov"},{"issue":"4","key":"4137_CR32","first-page":"376","volume":"73","author":"V Davalos","year":"2023","unstructured":"Davalos V, Esteller M. Cancer epigenetics in clinical practice. CA Cancer J Clin. 2023;73(4):376\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"4137_CR33","doi-asserted-by":"crossref","unstructured":"Zhang Y, Sun Z, Jia J, Du T, Zhang N, Tang Y, Fang Y, Fang D. Overview of histone modification. In: Histone mutations and cancer. 2020; p. 1\u20136.","DOI":"10.1007\/978-981-15-8104-5_1"},{"issue":"1","key":"4137_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12931-024-03093-6","volume":"26","author":"T Fan","year":"2025","unstructured":"Fan T, Xiao C, Deng Z, Li S, Tian H, Zheng Y, et al. Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9. Respir Res. 2025;26(1):17.","journal-title":"Respir Res"},{"issue":"2","key":"4137_CR35","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s11864-022-00949-1","volume":"23","author":"HK Walia","year":"2022","unstructured":"Walia HK, Sharma P, Singh N, Sharma S. Immunotherapy in small cell lung cancer treatment: a promising headway for future perspective. Curr Treat Options Oncol. 2022;23(2):268\u201394. https:\/\/doi.org\/10.1007\/s11864-022-00949-1.","journal-title":"Curr Treat Options Oncol"},{"issue":"4","key":"4137_CR36","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41419-022-04821-w","volume":"13","author":"L Zhao","year":"2022","unstructured":"Zhao L, Liu Y, Zhang S, Wei L, Cheng H, Wang J, et al. Impacts and mechanisms of metabolic reprogramming of tumor microenvironment for immunotherapy in gastric cancer. Cell Death Dis. 2022;13(4):378.","journal-title":"Cell Death Dis"},{"issue":"12","key":"4137_CR37","doi-asserted-by":"publisher","first-page":"e1226","DOI":"10.1002\/cti2.1226","volume":"9","author":"M Wang","year":"2020","unstructured":"Wang M, Wang S, Desai J, Trapani JA, Neeson PJ. Therapeutic strategies to remodel immunologically cold tumors. Clin Transl Immunol. 2020;9(12):e1226. https:\/\/doi.org\/10.1002\/cti2.1226.","journal-title":"Clin Transl Immunol"},{"issue":"7","key":"4137_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.it.2022.04.010","volume":"43","author":"J Zhang","year":"2022","unstructured":"Zhang J, Huang D, Saw PE, Song E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 2022;43(7):523\u201345.","journal-title":"Trends Immunol"},{"issue":"10","key":"4137_CR39","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.15252\/embj.201696151","volume":"36","author":"J Zhang","year":"2017","unstructured":"Zhang J, Pavlova NN, Thompson CB. Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. EMBO J. 2017;36(10):1302\u201315.","journal-title":"EMBO J"},{"issue":"1","key":"4137_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12964-024-02018-6","volume":"23","author":"D Nan","year":"2025","unstructured":"Nan D, Yao W, Huang L, Liu R, Chen X, Xia W, et al. Glutamine and cancer: metabolism, immune microenvironment, and therapeutic targets. Cell Commun Signal. 2025;23(1):45.","journal-title":"Cell Commun Signal"},{"issue":"11","key":"4137_CR41","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nrc.2016.89","volume":"16","author":"F R\u00f6hrig","year":"2016","unstructured":"R\u00f6hrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16(11):732\u201349. https:\/\/doi.org\/10.1038\/nrc.2016.89.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4137_CR42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/cancers14010250","volume":"14","author":"S Siddiqui","year":"2022","unstructured":"Siddiqui S, Glauben R. Fatty acid metabolism in myeloid-derived suppressor cells and tumor-associated macrophages: key factor in cancer immune evasion. Cancers. 2022;14(1):250.","journal-title":"Cancers"},{"issue":"9","key":"4137_CR43","doi-asserted-by":"publisher","first-page":"388","DOI":"10.5483\/BMBRep.2024-0031","volume":"57","author":"SA Lim","year":"2024","unstructured":"Lim SA. Metabolic reprogramming of the tumor microenvironment to enhance immunotherapy. BMB Rep. 2024;57(9):388.","journal-title":"BMB Rep"},{"issue":"10","key":"4137_CR44","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.3390\/cancers15102862","volume":"15","author":"A Casas-Benito","year":"2023","unstructured":"Casas-Benito A, Mart\u00ednez-Herrero S, Mart\u00ednez A. Succinate-directed approaches for Warburg effect-targeted cancer management, an alternative to current treatments? Cancers. 2023;15(10):2862.","journal-title":"Cancers"},{"issue":"3","key":"4137_CR45","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10787-017-0336-1","volume":"25","author":"A Kaur","year":"2017","unstructured":"Kaur A, Sharma S. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases. Inflammopharmacology. 2017;25(3):293\u2013312. https:\/\/doi.org\/10.1007\/s10787-017-0336-1.","journal-title":"Inflammopharmacology"},{"issue":"5","key":"4137_CR46","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3390\/antiox10050642","volume":"10","author":"S Arfin","year":"2021","unstructured":"Arfin S, Jha NK, Jha SK, Kesari KK, Ruokolainen J, Roychoudhury S, et al. Oxidative stress in cancer cell metabolism. Antioxidants. 2021;10(5):642.","journal-title":"Antioxidants"},{"issue":"6","key":"4137_CR47","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1089\/ars.2015.6580","volume":"25","author":"M Hornsveld","year":"2016","unstructured":"Hornsveld M, Dansen TB. The hallmarks of cancer from a redox perspective. Antioxid Redox Signal. 2016;25(6):300\u201325.","journal-title":"Antioxid Redox Signal"},{"issue":"7","key":"4137_CR48","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41571-019-0203-7","volume":"16","author":"X Li","year":"2019","unstructured":"Li X, Wenes M, Romero P, Huang SC, Fendt SM, Ho PC. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat Rev Clin Oncol. 2019;16(7):425\u201341. https:\/\/doi.org\/10.1038\/s41571-019-0203-7.","journal-title":"Nat Rev Clin Oncol"},{"key":"4137_CR49","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.semcancer.2022.12.001","volume":"88","author":"C Heuser","year":"2023","unstructured":"Heuser C, Renner K, Kreutz M, Gattinoni L. Targeting lactate metabolism for cancer immunotherapy\u2014a matter of precision. Semin Cancer Biol. 2023;88:32\u201345.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"4137_CR50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2174\/1574892813666180831102519","volume":"13","author":"W Li","year":"2018","unstructured":"Li W, Sun X. Recent advances in developing novel anti-cancer drugs targeting tumor hypoxic and acidic microenvironments. Recent Pat Anticancer Drug Discov. 2018;13(4):455\u201368.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"10","key":"4137_CR51","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/s41419-024-07122-6","volume":"15","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Xu R, Chen X, Lu Y, Zheng J, Lin Y, et al. Metabolic gatekeepers: harnessing tumor-derived metabolites to optimize T cell-based immunotherapy efficacy in the tumor microenvironment. Cell Death Dis. 2024;15(10):775.","journal-title":"Cell Death Dis"},{"issue":"8","key":"4137_CR52","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.3390\/cancers11111756","volume":"11","author":"K Marhelava","year":"2019","unstructured":"Marhelava K, Pilch Z, Bajor M, Graczyk-Jarzynka A, Zagozdzon R. Targeting negative and positive immune checkpoints with monoclonal antibodies in therapy of cancer. Cancers. 2019;11(8):1756.","journal-title":"Cancers"},{"issue":"17","key":"4137_CR53","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/EDBK_240837","volume":"39","author":"CM Fares","year":"2019","unstructured":"Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book. 2019;39(17):147\u201364.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"25","key":"4137_CR54","doi-asserted-by":"publisher","first-page":"883655","DOI":"10.3389\/fphar.2022.883655","volume":"13","author":"Z Xiang","year":"2022","unstructured":"Xiang Z, Li J, Zhang Z, Cen C, Chen W, Jiang B, et al. Comprehensive evaluation of anti-PD-1, anti-PD-L1, anti-CTLA-4 and their combined immunotherapy in clinical trials: a systematic review and meta-analysis. Front Pharmacol. 2022;13(25):883655.","journal-title":"Front Pharmacol"},{"issue":"2","key":"4137_CR55","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/14737140.2016.1211936","volume":"16","author":"P Specenier","year":"2016","unstructured":"Specenier P. Ipilimumab in melanoma. Expert Rev Anticancer Ther. 2016;16(2):811\u201326.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"4137_CR56","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.seminoncol.2017.06.007","volume":"44","author":"V Prasad","year":"2017","unstructured":"Prasad V, Kaestner V. Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. Semin Oncol. 2017;44(2):132\u20135.","journal-title":"Semin Oncol"},{"issue":"2","key":"4137_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10555-025-10260-8","volume":"44","author":"JJ Adashek","year":"2025","unstructured":"Adashek JJ, Moran JA, Le DT, Kurzrock R. Lessons learned from a decade of immune checkpoint inhibition: the good, the bad, and the ugly. Cancer Metastasis Rev. 2025;44(2):1\u20139.","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"4137_CR58","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23(1):781\u201392.","journal-title":"Lancet Oncol"},{"issue":"2","key":"4137_CR59","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/14740338.2022.1993819","volume":"21","author":"A Villani","year":"2022","unstructured":"Villani A, Ocampo-Garza SS, Potestio L, Fabbrocini G, Ocampo-Candiani J, Ocampo-Garza J, et al. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma. Expert Opin Drug Saf. 2022;21(2):21\u20139.","journal-title":"Expert Opin Drug Saf"},{"issue":"24","key":"4137_CR60","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1038\/s41467-023-37933-8","volume":"14","author":"JH Creemers","year":"2023","unstructured":"Creemers JH, Ankan A, Roes KC, Schr\u00f6der G, Mehra N, Figdor CG, et al. In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome. Nat Commun. 2023;14(24):2348.","journal-title":"Nat Commun"},{"issue":"27","key":"4137_CR61","doi-asserted-by":"publisher","first-page":"656364","DOI":"10.3389\/fimmu.2021.656364","volume":"12","author":"K Khalaf","year":"2021","unstructured":"Khalaf K, Hana D, Chou JT, Singh C, Mackiewicz A, Kaczmarek M. Aspects of the tumor microenvironment involved in immune resistance and drug resistance. Front Immunol. 2021;12(27):656364.","journal-title":"Front Immunol"},{"issue":"9","key":"4137_CR62","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41571-023-00789-4","volume":"20","author":"K Yang","year":"2023","unstructured":"Yang K, Halima A, Chan TA. Antigen presentation in cancer\u2014mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol. 2023;20(9):604\u201323. https:\/\/doi.org\/10.1038\/s41571-023-00789-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"4137_CR63","doi-asserted-by":"publisher","first-page":"944722","DOI":"10.3389\/fonc.2022.944722","volume":"12","author":"C Wang","year":"2022","unstructured":"Wang C, Wang Z, Yao T, Zhou J, Wang Z. The immune-related role of beta-2-microglobulin in melanoma. Front Oncol. 2022;12:944722.","journal-title":"Front Oncol"},{"issue":"6","key":"4137_CR64","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.3390\/ijms18061331","volume":"18","author":"M \u0160mahel","year":"2017","unstructured":"\u0160mahel M. PD-1\/PD-L1 blockade therapy for tumors with downregulated MHC class I expression. Int J Mol Sci. 2017;18(6):1331.","journal-title":"Int J Mol Sci"},{"key":"4137_CR65","doi-asserted-by":"publisher","first-page":"702726","DOI":"10.3389\/fimmu.2021.702726","volume":"12","author":"EN Scott","year":"2021","unstructured":"Scott EN, Gocher AM, Workman CJ, Vignali DA. Regulatory T cells: barriers of immune infiltration into the tumor microenvironment. Front Immunol. 2021;12:702726.","journal-title":"Front Immunol"},{"key":"4137_CR66","doi-asserted-by":"publisher","first-page":"1135456","DOI":"10.3389\/fonc.2023.1135456","volume":"13","author":"S Bruni","year":"2023","unstructured":"Bruni S, Mercogliano MF, Mauro FL, Russo RI, Schillaci R. Cancer immune exclusion: breaking the barricade for a successful immunotherapy. Front Oncol. 2023;13:1135456.","journal-title":"Front Oncol"},{"issue":"2","key":"4137_CR67","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/bfgp\/ely006","volume":"18","author":"QF He","year":"2019","unstructured":"He QF, Xu Y, Li J, Huang ZM, Li XH, Wang X. CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy. Brief Funct Genom. 2019;18(2):99\u2013106. https:\/\/doi.org\/10.1093\/bfgp\/ely006.","journal-title":"Brief Funct Genom"},{"key":"4137_CR68","doi-asserted-by":"publisher","first-page":"118005","DOI":"10.1016\/j.lfs.2020.118005","volume":"256","author":"N Khosravi","year":"2020","unstructured":"Khosravi N, Mokhtarzadeh A, Baghbanzadeh A, Hajiasgharzadeh K, Shahgoli VK, Hemmat N, et al. Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells. Life Sci. 2020;256:118005.","journal-title":"Life Sci"},{"issue":"1","key":"4137_CR69","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10238-023-01274-z","volume":"24","author":"K Mortezaee","year":"2024","unstructured":"Mortezaee K. WNT\/\u03b2-catenin regulatory roles on PD-(L) 1 and immunotherapy responses. Clin Exp Med. 2024;24(1):15.","journal-title":"Clin Exp Med"},{"key":"4137_CR70","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.3389\/fimmu.2019.02293","volume":"10","author":"X Li","year":"2019","unstructured":"Li X, Xiang Y, Li F, Yin C, Li B, Ke X. WNT\/\u03b2-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment. Front Immunol. 2019;10:2293.","journal-title":"Front Immunol"},{"key":"4137_CR71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2021.06.008","volume":"517","author":"H Wang","year":"2021","unstructured":"Wang H, Liu B, Wei J. Beta2-microglobulin (B2M) in cancer immunotherapies: biological function, resistance and remedy. Cancer Lett. 2021;517:96\u2013104.","journal-title":"Cancer Lett"},{"issue":"4","key":"4137_CR72","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3390\/vaccines7040149","volume":"7","author":"R Saleh","year":"2019","unstructured":"Saleh R, Toor SM, Khalaf S, Elkord E. Breast cancer cells and PD-1\/PD-L1 blockade upregulate the expression of PD-1, CTLA-4, TIM-3 and LAG-3 immune checkpoints in CD4+ T cells. Vaccines. 2019;7(4):149.","journal-title":"Vaccines"},{"issue":"1","key":"4137_CR73","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.12766","volume":"290","author":"BA Wilky","year":"2019","unstructured":"Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. Immunol Rev. 2019;290(1):6\u201323. https:\/\/doi.org\/10.1111\/imr.12766.","journal-title":"Immunol Rev"},{"issue":"7","key":"4137_CR74","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/biom10071061","volume":"10","author":"A Perrier","year":"2020","unstructured":"Perrier A, Didelot A, Laurent-Puig P, Blons H, Garinet S. Epigenetic mechanisms of resistance to immune checkpoint inhibitors. Biomolecules. 2020;10(7):1061.","journal-title":"Biomolecules"},{"key":"4137_CR75","doi-asserted-by":"publisher","first-page":"641428","DOI":"10.3389\/fonc.2021.641428","volume":"11","author":"BL Russell","year":"2021","unstructured":"Russell BL, Sooklal SA, Malindisa ST, Daka LJ, Ntwasa M. The tumor microenvironment factors that promote resistance to immune checkpoint blockade therapy. Front Oncol. 2021;11:641428.","journal-title":"Front Oncol"},{"issue":"1","key":"4137_CR76","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13148-021-01100-x","volume":"13","author":"JD Licht","year":"2021","unstructured":"Licht JD, Bennett RL. Leveraging epigenetics to enhance the efficacy of immunotherapy. Clin Epigenetics. 2021;13(1):115.","journal-title":"Clin Epigenetics"},{"issue":"5","key":"4137_CR77","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","volume":"24","author":"P Meier","year":"2024","unstructured":"Meier P, Legrand AJ, Adam D, Silke J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat Rev Cancer. 2024;24(5):299\u2013315. https:\/\/doi.org\/10.1038\/s41568-024-00674-x.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"4137_CR78","doi-asserted-by":"publisher","first-page":"2303799","DOI":"10.1080\/21645515.2024.2303799","volume":"20","author":"B Aparicio","year":"2024","unstructured":"Aparicio B, Theunissen P, Hervas-Stubbs S, Fortes P, Sarobe P. Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies. Hum Vaccin Immunother. 2024;20(1):2303799.","journal-title":"Hum Vaccin Immunother"},{"key":"4137_CR79","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, Gharibvand RS, Eskandari N. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 2024;44:521\u201353.","journal-title":"Cancer Commun"},{"issue":"15","key":"4137_CR80","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.3390\/cancers17152484","volume":"17","author":"JS Pawar","year":"2025","unstructured":"Pawar JS, Salam MA, Dipto MS, Al-Amin MY, Salam MT, Sengupta S, et al. Cancer-Associated fibroblasts: immunosuppressive crosstalk with tumor-infiltrating immune cells and implications for therapeutic resistance. Cancers. 2025;17(15):2484.","journal-title":"Cancers"},{"issue":"1","key":"4137_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/onc.2016.182","volume":"36","author":"F R\u00f6hrig","year":"2017","unstructured":"R\u00f6hrig F, Vorlov\u00e1 S, Hoffmann H, Wartenberg M, Escorcia FE, Keller S, et al. VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors. Oncogene. 2017;36(1):1\u20132.","journal-title":"Oncogene"},{"issue":"12","key":"4137_CR82","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1158\/0008-5472.CAN-24-4744","volume":"85","author":"L Liu","year":"2025","unstructured":"Liu L, Zhang Y, Liu H, Yang J, Tian Q, Chueakula N, et al. Transforming cancer therapy: unlocking the potential of targeting vascular and stromal cells in the tumor microenvironment. Cancer Res. 2025;85(12):2152\u201364.","journal-title":"Cancer Res"},{"issue":"9","key":"4137_CR83","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1007\/s00259-024-06704-y","volume":"51","author":"G Bao","year":"2024","unstructured":"Bao G, Wang Z, Liu L, Zhang B, Song S, Wang D, et al. Targeting CXCR4\/CXCL12 axis via [177Lu] Lu-DOTAGA.(SA. FAPi) 2 with CXCR4 antagonist in triple-negative breast cancer. Eur J Nucl Med Mol Imaging. 2024;51(9):2744\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"4137_CR84","doi-asserted-by":"publisher","first-page":"e184321","DOI":"10.1172\/JCI184321","volume":"135","author":"FS Gazzaniga","year":"2025","unstructured":"Gazzaniga FS, Kasper DL. The gut microbiome and cancer response to immune checkpoint inhibitors. J Clin Investig. 2025;135(3):e184321.","journal-title":"J Clin Investig"},{"issue":"2","key":"4137_CR85","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/PPO.0000000000000647","volume":"29","author":"H Attebury","year":"2023","unstructured":"Attebury H, Daley D. The gut microbiome and pancreatic cancer development and treatment. Cancer J. 2023;29(2):49\u201356.","journal-title":"Cancer J"},{"issue":"6","key":"4137_CR86","doi-asserted-by":"publisher","first-page":"e20241102","DOI":"10.1084\/jem.20241102","volume":"222","author":"AB Plata-G\u00f3mez","year":"2025","unstructured":"Plata-G\u00f3mez AB, Ho PC. Age-and diet-instructed metabolic rewiring of the tumor-immune microenvironment. J Exp Med. 2025;222(6):e20241102.","journal-title":"J Exp Med"},{"issue":"10","key":"4137_CR87","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41571-018-0036-9","volume":"15","author":"R Xu","year":"2018","unstructured":"Xu R, Rai A, Chen M, Suwakulsiri W, Greening DW, Simpson RJ. Extracellular vesicles in cancer\u2014implications for future improvements in cancer care. Nat Rev Clin Oncol. 2018;15(10):617\u201338. https:\/\/doi.org\/10.1038\/s41571-018-0036-9.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"4137_CR88","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s12943-023-01898-5","volume":"22","author":"M Yue","year":"2023","unstructured":"Yue M, Hu S, Sun H, Tuo B, Jia B, Chen C, et al. Extracellular vesicles remodel tumor environment for cancer immunotherapy. Mol Cancer. 2023;22(1):203.","journal-title":"Mol Cancer"},{"issue":"3","key":"4137_CR89","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s00441-022-03650-9","volume":"389","author":"Q Ou","year":"2022","unstructured":"Ou Q, Dou X, Tang J, Wu P, Pan D. Small extracellular vesicles derived from PD-L1-modified mesenchymal stem cell promote Tregs differentiation and prolong allograft survival. Cell Tissue Res. 2022;389(3):465\u201381. https:\/\/doi.org\/10.1007\/s00441-022-03650-9.","journal-title":"Cell Tissue Res"},{"issue":"4","key":"4137_CR90","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41577-022-00763-8","volume":"23","author":"EI Buzas","year":"2023","unstructured":"Buzas EI. The roles of extracellular vesicles in the immune system. Nat Rev Immunol. 2023;23(4):236\u201350. https:\/\/doi.org\/10.1038\/s41577-022-00763-8.","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"4137_CR91","doi-asserted-by":"publisher","first-page":"e12490","DOI":"10.1002\/jev2.12490","volume":"13","author":"R Chen","year":"2024","unstructured":"Chen R, Kang Z, Li W, Xu T, Wang Y, Jiang Q, et al. Extracellular vesicle surface display of \u03b1PD\u2010L1 and \u03b1CD3 antibodies via engineered late domain\u2010based scaffold to activate T\u2010cell anti\u2010tumor immunity. J Extracell Vesicles. 2024;13(7):e12490. https:\/\/doi.org\/10.1002\/jev2.12490.","journal-title":"J Extracell Vesicles"},{"issue":"4","key":"4137_CR92","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41418-019-0297-6","volume":"26","author":"N Germic","year":"2019","unstructured":"Germic N, Frangez Z, Yousefi S, Simon HU. Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation. Cell Death Differ. 2019;26(4):715\u201327. https:\/\/doi.org\/10.1038\/s41418-019-0297-6.","journal-title":"Cell Death Differ"},{"issue":"11","key":"4137_CR93","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1038\/s41423-021-00764-y","volume":"18","author":"J Chen","year":"2021","unstructured":"Chen J, Huang F, Hou Y, Lin X, Liang R, Hu X, et al. TGF-\u03b2-induced CD4+ FoxP3+ regulatory T cell-derived extracellular vesicles modulate Notch1 signaling through miR-449a and prevent collagen-induced arthritis in a murine model. Cell Mol Immunol. 2021;18(11):2516\u201329.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"4137_CR94","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jhg.2016.87","volume":"62","author":"T Kinoshita","year":"2017","unstructured":"Kinoshita T, Yip KW, Spence T, Liu FF. MicroRNAs in extracellular vesicles: potential cancer biomarkers. J Hum Genet. 2017;62(1):67\u201374. https:\/\/doi.org\/10.1038\/jhg.2016.87.","journal-title":"J Hum Genet"},{"issue":"19","key":"4137_CR95","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.7150\/jca.98426","volume":"15","author":"R Mir","year":"2024","unstructured":"Mir R, Baba SK, Elfaki I, Algehainy N, Alanazi MA, Altemani FH, et al. Unlocking the secrets of extracellular vesicles: orchestrating tumor microenvironment dynamics in metastasis, drug resistance, and immune evasion. J Cancer. 2024;15(19):6383.","journal-title":"J Cancer"},{"issue":"9","key":"4137_CR96","doi-asserted-by":"publisher","first-page":"2102620","DOI":"10.1002\/advs.202102620","volume":"9","author":"Y Yin","year":"2022","unstructured":"Yin Y, Liu B, Cao Y, Yao S, Liu Y, Jin G, et al. Colorectal cancer\u2010derived small extracellular vesicles promote tumor immune evasion by upregulating PD\u2010L1 expression in tumor\u2010associated macrophages. Adv Sci. 2022;9(9):2102620. https:\/\/doi.org\/10.1002\/advs.202102620.","journal-title":"Adv Sci"},{"issue":"5","key":"4137_CR97","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.3390\/cells9051141","volume":"9","author":"CP Xavier","year":"2020","unstructured":"Xavier CP, Caires HR, Barbosa MA, Bergantim R, Guimaraes JE. The role of extracellular vesicles in the hallmarks of cancer and drug resistance. Cells. 2020;9(5):1141.","journal-title":"Cells"},{"issue":"1","key":"4137_CR98","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-019-0967-5","volume":"18","author":"T Huang","year":"2019","unstructured":"Huang T, Song C, Zheng L, Xia L, Li Y, Zhou Y. The roles of extracellular vesicles in gastric cancer development, microenvironment, anti-cancer drug resistance, and therapy. Mol Cancer. 2019;18(1):62.","journal-title":"Mol Cancer"},{"issue":"21","key":"4137_CR99","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.3390\/cancers14215415","volume":"14","author":"Y Zeng","year":"2022","unstructured":"Zeng Y, Qiu Y, Jiang W, Fu BM. Glycocalyx acts as a central player in the development of tumor microenvironment by extracellular vesicles for angiogenesis and metastasis. Cancers. 2022;14(21):5415.","journal-title":"Cancers"},{"issue":"12","key":"4137_CR100","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725\u201341. https:\/\/doi.org\/10.1038\/s41571-020-0413-z.","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"4137_CR101","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.3390\/cancers12123558","volume":"12","author":"I Fern\u00e1ndez-Delgado","year":"2020","unstructured":"Fern\u00e1ndez-Delgado I, Calzada-Fraile D, S\u00e1nchez-Madrid F. Immune regulation by dendritic cell extracellular vesicles in cancer immunotherapy and vaccines. Cancers. 2020;12(12):3558.","journal-title":"Cancers"},{"issue":"3","key":"4137_CR102","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/cei\/uxac006","volume":"207","author":"X Dou","year":"2022","unstructured":"Dou X, Hua Y, Chen Z, Chao F, Li M. Extracellular vesicles containing PD-L1 contribute to CD8+ T-cell immune suppression and predict poor outcomes in small cell lung cancer. Clin Exp Immunol. 2022;207(3):307\u201317.","journal-title":"Clin Exp Immunol"},{"issue":"13","key":"4137_CR103","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.3390\/cells12131787","volume":"12","author":"A Benoit","year":"2023","unstructured":"Benoit A, Vogin G, Duhem C, Berchem G, Janji B. Lighting up the fire in the microenvironment of cold tumors: a major challenge to improve cancer immunotherapy. Cells. 2023;12(13):1787.","journal-title":"Cells"},{"key":"4137_CR104","doi-asserted-by":"publisher","first-page":"1593834","DOI":"10.3389\/fimmu.2025.1593834","volume":"16","author":"Nidhi","year":"2025","unstructured":"Nidhi, Yadav V, Singh T, Sharma D, Bohot M, Satapathy SR. Beyond boundaries: exploring the role of extracellular vesicles in organ-specific metastasis in solid tumors. Front Immunol. 2025;16:1593834.","journal-title":"Front Immunol"},{"key":"4137_CR105","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.semcdb.2015.01.013","volume":"40","author":"J Webber","year":"2015","unstructured":"Webber J, Yeung V, Clayton A. Extracellular vesicles as modulators of the cancer microenvironment. Semin Cell Dev Biol. 2015;40:27\u201334.","journal-title":"Semin Cell Dev Biol"},{"key":"4137_CR106","doi-asserted-by":"crossref","unstructured":"Rao C, Cater DT, Roy S, Xu J, De Oliveira AG, Evans-Molina C, Piganelli JD, Eizirik DL, Mirmira RG, Sims EK. Beta cell\nextracellular vesicle PD-L1 as a novel regulator of CD8+ T cell activity and biomarker during the evolution of type 1 diabetes.\nDiabetologia. 2025;68(2):382\u201396.","DOI":"10.1007\/s00125-024-06313-2"},{"issue":"23","key":"4137_CR107","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.3390\/jcm11236892","volume":"11","author":"A Reale","year":"2022","unstructured":"Reale A, Khong T, Spencer A. Extracellular vesicles and their roles in the tumor immune microenvironment. J Clin Med. 2022;11(23):6892.","journal-title":"J Clin Med"},{"key":"4137_CR108","first-page":"21","volume":"8","author":"J Yu","year":"2025","unstructured":"Yu J, Kong X, Feng Y. Tumor microenvironment-driven resistance to immunotherapy in non-small cell lung cancer: strategies for cold-to-hot tumor transformation. Cancer Drug Resist. 2025;8:21.","journal-title":"Cancer Drug Resist"},{"issue":"1","key":"4137_CR109","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1186\/s12885-024-13073-0","volume":"24","author":"M Carucci","year":"2024","unstructured":"Carucci M, Clamp A, Zhou C, Hurt C, Glasspool R, Monaghan PJ, et al. The VALTIVE1 study protocol: a study for the validation of Tie2 as the first tumour vascular response biomarker for VEGF inhibitors. BMC Cancer. 2024;24(1):1309.","journal-title":"BMC Cancer"},{"key":"4137_CR110","doi-asserted-by":"crossref","unstructured":"Powles T, Motzer RJ, Escudier BJ, Pal SK, Kollmannsberger CK, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M. Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC). J Clin Oncol. 2016;34:4557.","DOI":"10.1200\/JCO.2016.34.15_suppl.4557"},{"issue":"4","key":"4137_CR111","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/bcp.13495","volume":"84","author":"N Al\u2010Huniti","year":"2018","unstructured":"Al\u2010Huniti N, Petersson K, Tang W, Masson E, Li J. Population exposure-safety analysis of cediranib for phase I and II studies in patients with cancer. Br J Clin Pharmacol. 2018;84(4):726\u201337. https:\/\/doi.org\/10.1111\/bcp.13495.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"4137_CR112","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4081\/oncol.2022.561","volume":"16","author":"L Szablewski","year":"2022","unstructured":"Szablewski L. Glucose transporters as markers of diagnosis and prognosis in cancer diseases. Oncol Rev. 2022;16(1):561.","journal-title":"Oncol Rev"},{"issue":"14","key":"4137_CR113","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.2174\/1871520618666181025091128","volume":"18","author":"R Dogra","year":"2018","unstructured":"Dogra R, Bhatia R, Shankar R, Bansal P, Rawal RK. Enasidenib: first mutant IDH2 inhibitor for the treatment of refractory and relapsed acute myeloid leukemia. Anti-Cancer Agents Med Chem (Former Curr Med Chem Anti-Cancer Agents). 2018;18(14):1936\u201351.","journal-title":"Anti-Cancer Agents Med Chem"},{"issue":"10","key":"4137_CR114","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1080\/13543776.2021.1924150","volume":"31","author":"DA Sabbah","year":"2021","unstructured":"Sabbah DA, Hajjo R, Bardaweel SK, Zhong HA. Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016\u20132020). Expert Opin Ther Pat. 2021;31(10):877\u201392.","journal-title":"Expert Opin Ther Pat"},{"issue":"13","key":"4137_CR115","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1200\/JCO.2017.72.7107","volume":"36","author":"D Juric","year":"2018","unstructured":"Juric D, Rodon J, Tabernero J, Janku F, Burris HA, Schellens JH, et al. Phosphatidylinositol 3-kinase \u03b1-selective inhibition with alpelisib (BYL719) in PIK3CA-altered solid tumors: results from the first-in-human study. J Clin Oncol. 2018;36(13):1291\u20139.","journal-title":"J Clin Oncol"},{"key":"4137_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0349-3","volume":"6","author":"YK Chae","year":"2018","unstructured":"Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, et al. Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer. 2018;6:1\u201327.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"4137_CR117","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","volume":"36","author":"KD Courtney","year":"2018","unstructured":"Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, et al. Phase I dose-escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol. 2018;36(9):867\u201374.","journal-title":"J Clin Oncol"},{"key":"4137_CR118","doi-asserted-by":"publisher","first-page":"1664292","DOI":"10.3389\/fcell.2025.1664292","volume":"13","author":"J Yang","year":"2025","unstructured":"Yang J, Miao D, Li X, Zhao C, Tan D, Wu S, et al. Emerging roles of metabolic biomarkers in renal cell carcinoma: from molecular mechanisms to clinical implications. Front Cell Dev Biol. 2025;13:1664292.","journal-title":"Front Cell Dev Biol"},{"key":"4137_CR119","doi-asserted-by":"publisher","first-page":"1072651","DOI":"10.3389\/fphar.2022.1072651","volume":"13","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Wang G, Li Y, Lei D, Xiang J, Ouyang L, et al. Recent progress in DNA methyltransferase inhibitors as anticancer agents. Front Pharmacol. 2022;13:1072651.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4137_CR120","first-page":"59","volume":"10","author":"D Xiong","year":"2023","unstructured":"Xiong D, Zhang L, Sun ZJ. Targeting the epigenome to reinvigorate T cells for cancer immunotherapy. Mil Med Res. 2023;10(1):59.","journal-title":"Mil Med Res"},{"key":"4137_CR121","doi-asserted-by":"publisher","first-page":"1308264","DOI":"10.3389\/fimmu.2023.1308264","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y, Wang L, Ma P, Ju D, Zhao M, Shi Y. Enhancing anti-tumor immune responses through combination therapies: epigenetic drugs and immune checkpoint inhibitors. Front Immunol. 2023;14:1308264.","journal-title":"Front Immunol"},{"issue":"7","key":"4137_CR122","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.tibtech.2020.10.012","volume":"39","author":"JH Goell","year":"2021","unstructured":"Goell JH, Hilton IB. CRISPR\/Cas-based epigenome editing: advances, applications, and clinical utility. Trends Biotechnol. 2021;39(7):678\u201391.","journal-title":"Trends Biotechnol"},{"key":"4137_CR123","doi-asserted-by":"publisher","first-page":"1122352","DOI":"10.3389\/fimmu.2023.1122352","volume":"14","author":"C Jie","year":"2023","unstructured":"Jie C, Li R, Cheng Y, Wang Z, Wu Q, Xie C. Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer. Front Immunol. 2023;14:1122352.","journal-title":"Front Immunol"},{"issue":"1","key":"4137_CR124","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1724600820980739","volume":"36","author":"Y Heo","year":"2021","unstructured":"Heo Y, Heo J, Han SS, Kim WJ, Cheong HS, Hong Y. Difference of copy number variation in blood of patients with lung cancer. Int J Biol Markers. 2021;36(1):3\u20139. https:\/\/doi.org\/10.1177\/1724600820980739.","journal-title":"Int J Biol Markers"},{"key":"4137_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0660-7","volume":"7","author":"L Cai","year":"2019","unstructured":"Cai L, Bai H, Duan J, Wang Z, Gao S, Wang D, et al. Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. J Immunother Cancer. 2019;7:1\u20131.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4137_CR126","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-020-00209-0","volume":"8","author":"R Bai","year":"2020","unstructured":"Bai R, Lv Z, Xu D, Cui J. Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors. Biomark Res. 2020;8(1):34.","journal-title":"Biomark Res"},{"issue":"8","key":"4137_CR127","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s41417-021-00422-5","volume":"29","author":"F Kou","year":"2022","unstructured":"Kou F, Wu L, Zhu Y, Li B, Huang Z, Ren X, et al. Somatic copy number alteration predicts clinical benefit of lung adenocarcinoma patients treated with cytokine-induced killer plus chemotherapy. Cancer Gene Ther. 2022;29(8):1153\u20139. https:\/\/doi.org\/10.1038\/s41417-021-00422-5.","journal-title":"Cancer Gene Ther"},{"issue":"21","key":"4137_CR128","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.7150\/thno.26650","volume":"8","author":"J Fan","year":"2018","unstructured":"Fan J, Wei Q, Koay EJ, Liu Y, Ning B, Bernard PW, et al. Chemoresistance transmission via exosome-mediated EphA2 transfer in pancreatic cancer. Theranostics. 2018;8(21):5986.","journal-title":"Theranostics"},{"key":"4137_CR129","doi-asserted-by":"crossref","unstructured":"Liao H, Zhang C, Wang F, Jin F, Zhao Q, Wang X, Wang S, Gao J. Tumor-derived extracellular vesicle proteins as new\nbiomarkers and targets in precision oncology. J Mol Med. 2024;102(8):961\u201371.","DOI":"10.1007\/s00109-024-02452-6"},{"issue":"22","key":"4137_CR130","doi-asserted-by":"publisher","first-page":"5633","DOI":"10.3390\/cancers13225633","volume":"13","author":"M Saviana","year":"2021","unstructured":"Saviana M, Romano G, Le P, Acunzo M, Nana-Sinkam P. Extracellular vesicles in lung cancer metastasis and their clinical applications. Cancers. 2021;13(22):5633.","journal-title":"Cancers"},{"key":"4137_CR131","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/bs.ai.2016.01.001","volume":"130","author":"JP Ward","year":"2016","unstructured":"Ward JP, Gubin MM, Schreiber RD. The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv Immunol. 2016;130:25\u201374.","journal-title":"Adv Immunol"},{"issue":"12","key":"4137_CR132","doi-asserted-by":"publisher","first-page":"12391","DOI":"10.1002\/jev2.12391","volume":"12","author":"C Zhai","year":"2023","unstructured":"Zhai C, Xie F, Xu J, Yang Y, Zheng W, Hu H, et al. Correlation between membrane proteins and sizes of extracellular vesicles and particles: a potential signature for cancer diagnosis. J Extracell Vesicles. 2023;12(12):12391. https:\/\/doi.org\/10.1002\/jev2.12391.","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"4137_CR133","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12885-024-11819-4","volume":"8","author":"M Andre","year":"2024","unstructured":"Andre M, Caobi A, Miles JS, Vashist A, Ruiz MA, Raymond AD. Diagnostic potential of exosomal extracellular vesicles in oncology. BMC Cancer. 2024;8(1):322.","journal-title":"BMC Cancer"},{"key":"4137_CR134","doi-asserted-by":"publisher","first-page":"1459178","DOI":"10.3389\/fonc.2024.1459178","volume":"11","author":"AS Manap","year":"2024","unstructured":"Manap AS, Ngwenya FM, Selvan MK, Arni S, Hassan FH, Rudy AD, et al. Lung cancer cell-derived exosomes: progress on pivotal role and its application in diagnostic and therapeutic potential. Front Oncol. 2024;11:1459178.","journal-title":"Front Oncol"},{"issue":"1","key":"4137_CR135","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12943-023-01875-y","volume":"7","author":"YN Yang","year":"2023","unstructured":"Yang YN, Zhang J, Zhang W, Wang Y, Zhai Y, Li Y, et al. A liquid biopsy signature of circulating extracellular vesicles-derived RNAs predicts response to first line chemotherapy in patients with metastatic colorectal cancer. Mol Cancer. 2023;7(1):199.","journal-title":"Mol Cancer"},{"issue":"1","key":"4137_CR136","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1038\/s41467-021-22913-7","volume":"5","author":"F Tian","year":"2021","unstructured":"Tian F, Zhang S, Liu C, Han Z, Liu Y, Deng J, et al. Protein analysis of extracellular vesicles to monitor and predict therapeutic response in metastatic breast cancer. Nat Commun. 2021;5(1):2536.","journal-title":"Nat Commun"},{"issue":"3","key":"4137_CR137","doi-asserted-by":"publisher","first-page":"e12418","DOI":"10.1002\/jev2.12418","volume":"13","author":"N Sch\u00f6ne","year":"2024","unstructured":"Sch\u00f6ne N, Kemper M, Menck K, Evers G, Krekeler C, Schulze AB, et al. PD\u2010L1 on large extracellular vesicles is a predictive biomarker for therapy response in tissue PD\u2010L1\u2010low and\u2010negative patients with non\u2010small cell lung cancer. J Extracell Vesicles. 2024;13(3):e12418. https:\/\/doi.org\/10.1002\/jev2.12418.","journal-title":"J Extracell Vesicles"},{"issue":"10278","key":"4137_CR138","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","volume":"13","author":"F Meric-Bernstam","year":"2021","unstructured":"Meric-Bernstam F, Larkin J, Tabernero J, Bonini C. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2021;13(10278):1010\u201322.","journal-title":"Lancet"},{"issue":"4","key":"4137_CR139","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/0008-5472.CAN-23-2006","volume":"15","author":"J Yang","year":"2024","unstructured":"Yang J, Liu Q, Shyr Y. A large-scale meta-analysis reveals positive feedback between macrophages and T cells that sensitizes tumors to immunotherapy. Cancer Res. 2024;15(4):626\u201338.","journal-title":"Cancer Res"},{"key":"4137_CR140","doi-asserted-by":"publisher","first-page":"1151224","DOI":"10.3389\/fimmu.2023.1151224","volume":"25","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang S, Wang Y, Li Y, Zhu X, Lai X, et al. What makes TMB an ambivalent biomarker for immunotherapy? A subtle mismatch between the sample-based design of variant callers and real clinical cohort. Front Immunol. 2023;25:1151224.","journal-title":"Front Immunol"},{"issue":"17","key":"4137_CR141","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1158\/1078-0432.CCR-21-0327","volume":"1","author":"L Marcus","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, Yuan M, Rodriguez L, Gallagher PS, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021;1(17):4685\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4137_CR142","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","volume":"7","author":"A Forschner","year":"2019","unstructured":"Forschner A, Battke F, Hadaschik D, Schulze M, Wei\u00dfgraeber S, Han CT, et al. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma\u2014results of a prospective biomarker study. J Immunother Cancer. 2019;7(1):180.","journal-title":"J Immunother Cancer"},{"key":"4137_CR143","first-page":"100746","volume":"36","author":"IA Voutsadakis","year":"2023","unstructured":"Voutsadakis IA. High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: diverse molecular associations point to variable pathophysiology. Cancer Treat Res Commun. 2023;36:100746.","journal-title":"Cancer Treat Res Commun"},{"key":"4137_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-018-0342-x","volume":"6","author":"MM Boyiadzis","year":"2018","unstructured":"Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL. Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J Immunother Cancer. 2018;6:1\u20137.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"4137_CR145","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.annonc.2024.03.009","volume":"35","author":"M Ambrosini","year":"2024","unstructured":"Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, Andr\u00e9 T, et al. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024;35(7):643\u201355.","journal-title":"Ann Oncol"},{"issue":"8","key":"4137_CR146","doi-asserted-by":"publisher","first-page":"930","DOI":"10.3390\/vaccines12080930","volume":"12","author":"J Liang","year":"2024","unstructured":"Liang J, Liao Y, Tu Z, Liu J. Revamping hepatocellular carcinoma immunotherapy: the advent of microbial neoantigen vaccines. Vaccines (Basel). 2024;12(8):930.","journal-title":"Vaccines (Basel)"},{"key":"4137_CR147","doi-asserted-by":"crossref","unstructured":"El-Deiry WS, Arnoff T, Sahin I, Borghaei H, Subbiah V, Khan H, Carneiro BA, Safran H, Graff SL, Dizon DS, Heath EI. A pancancer analysis of impact of MDM2\/MDM4 on immune checkpoint blockade (ICB). J clin Oncol. 40:2630.","DOI":"10.1200\/JCO.2022.40.16_suppl.2630"},{"issue":"5","key":"4137_CR148","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.3390\/ijms24054422","volume":"24","author":"HT Tzeng","year":"2023","unstructured":"Tzeng HT, Huang YJ. Tumor vasculature as an emerging pharmacological target to promote anti-tumor immunity. Int J Mol Sci. 2023;24(5):4422.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4137_CR149","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","volume":"10","author":"P Sharma","year":"2024","unstructured":"Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O\u2019Dea A, et al. Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol. 2024;10(2):227\u201335.","journal-title":"JAMA Oncol"},{"key":"4137_CR150","doi-asserted-by":"publisher","first-page":"189187","DOI":"10.1016\/j.bbcan.2024.189187","volume":"1879","author":"WJ Qian","year":"2024","unstructured":"Qian WJ, Yan JS, Gang XY, Xu L, Shi S, Li X, et al. Intercellular adhesion molecule-1 (ICAM-1): from molecular functions to clinical applications in cancer investigation. Biochim Biophys Acta (BBA)-Rev Cancer. 2024;1879:189187.","journal-title":"Biochim Biophys Acta (BBA)-Rev Cancer"},{"key":"4137_CR151","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.3389\/fimmu.2020.02105","volume":"11","author":"F Maibach","year":"2020","unstructured":"Maibach F, Sadozai H, Seyed Jafari SM, Hunger RE, Schenk M. Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front Immunol. 2020;11:2105.","journal-title":"Front Immunol"},{"issue":"2","key":"4137_CR152","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3390\/ijms25020921","volume":"25","author":"I Carrera-Aguado","year":"2024","unstructured":"Carrera-Aguado I, Marcos-Zazo L, Carrancio-Sal\u00e1n P, Guerra-Paes E, S\u00e1nchez-Juanes F, Mu\u00f1oz-F\u00e9lix JM. The inhibition of vessel co-option as an emerging strategy for cancer therapy. Int J Mol Sci. 2024;25(2):921.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"4137_CR153","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S1470-2045(12)70231-0","volume":"13","author":"D Lambrechts","year":"2012","unstructured":"Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, et al. VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials. Lancet Oncol. 2012;13(7):724\u201333.","journal-title":"Lancet Oncol"},{"issue":"5","key":"4137_CR154","doi-asserted-by":"publisher","first-page":"598","DOI":"10.37349\/etat.2022.00103","volume":"3","author":"J Thiery","year":"2022","unstructured":"Thiery J. Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions. Explor Target Anti-tumor Ther. 2022;3(5):598.","journal-title":"Explor Target Anti-tumor Ther"},{"issue":"1","key":"4137_CR155","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.drudis.2020.06.029","volume":"25","author":"X He","year":"2020","unstructured":"He X, Yang Y, Li L, Zhang P, Guo H, Liu N, et al. Engineering extracellular matrix to improve drug delivery for cancer therapy. Drug Discov Today. 2020;25(1):1727\u201334.","journal-title":"Drug Discov Today"},{"issue":"4","key":"4137_CR156","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/s42255-019-0045-8","volume":"1","author":"Y Ye","year":"2019","unstructured":"Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y, et al. Characterization of hypoxia-associated molecular features to aid hypoxia-targeted therapy. Nat Metab. 2019;1(4):431\u201344. https:\/\/doi.org\/10.1038\/s42255-019-0045-8.","journal-title":"Nat Metab"},{"issue":"24","key":"4137_CR157","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3389\/fimmu.2020.01590","volume":"11","author":"E Peranzoni","year":"2020","unstructured":"Peranzoni E, Ingangi V, Masetto E, Pinton L, Marigo I. Myeloid cells as clinical biomarkers for immune checkpoint blockade. Front Immunol. 2020;11(24):1590.","journal-title":"Front Immunol"},{"issue":"19","key":"4137_CR158","doi-asserted-by":"publisher","first-page":"40767","DOI":"10.18632\/oncotarget.8194","volume":"7","author":"YK Chae","year":"2016","unstructured":"Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, et al. Repurposing metformin for cancer treatment: current clinical studies. Oncotarget. 2016;7(19):40767.","journal-title":"Oncotarget"},{"issue":"17","key":"4137_CR159","doi-asserted-by":"publisher","first-page":"1156821","DOI":"10.3389\/fmolb.2023.1156821","volume":"10","author":"T Soleymani","year":"2023","unstructured":"Soleymani T, Chen TY, Gonzalez-Kozlova E, Dogra N. The human neurosecretome: extracellular vesicles and particles (EVPs) of the brain for intercellular communication, therapy, and liquid-biopsy applications. Front Mol Biosci. 2023;10(17):1156821.","journal-title":"Front Mol Biosci"},{"issue":"11","key":"4137_CR160","doi-asserted-by":"publisher","first-page":"5674","DOI":"10.3390\/ijms22115674","volume":"22","author":"I Tatischeff","year":"2021","unstructured":"Tatischeff I. Current search through liquid biopsy of effective biomarkers for early cancer diagnosis into the rich cargoes of extracellular vesicles. Int J Mol Sci. 2021;22(11):5674.","journal-title":"Int J Mol Sci"},{"issue":"16","key":"4137_CR161","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3389\/fendo.2020.00382","volume":"11","author":"TY Huang","year":"2020","unstructured":"Huang TY, Wang CY, Chen KY, Huang LT. Urinary exosomal thyroglobulin in thyroid cancer patients with post-ablative therapy: a new biomarker in thyroid cancer. Front Endocrinol. 2020;11(16):382.","journal-title":"Front Endocrinol"},{"key":"4137_CR162","doi-asserted-by":"publisher","first-page":"4667","DOI":"10.2147\/IJN.S458931","volume":"31","author":"CY Wang","year":"2024","unstructured":"Wang CY, Shih SR, Chen KY, Chung YC, Huang PJ. Long-term changes of urinary exosomal peptide levels after thyroidectomy in patients with thyroid cancer: a prospective observational study. Int J Nanomed. 2024;31:4667\u201377.","journal-title":"Int J Nanomed"},{"issue":"18","key":"4137_CR163","doi-asserted-by":"publisher","first-page":"1097117","DOI":"10.3389\/fimmu.2022.1097117","volume":"13","author":"S Akbar","year":"2023","unstructured":"Akbar S, Raza A, Mohsin R, Kanbour A, Qadri S, Parray A, et al. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1\/PD-L1 therapy in non-small cell lung cancer patients. Front Immunol. 2023;13(18):1097117.","journal-title":"Front Immunol"},{"key":"4137_CR164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-019-0965-7","volume":"18","author":"S Maacha","year":"2019","unstructured":"Maacha S, Bhat AA, Jimenez L, Raza A, Haris M, Uddin S, et al. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Mol Cancer. 2019;18:1\u20136.","journal-title":"Mol Cancer"},{"issue":"3","key":"4137_CR165","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/molecules30030498","volume":"30","author":"H Zhang","year":"2025","unstructured":"Zhang H, Wu B, Wang Y, Du H, Fang L. Extracellular vesicles as mediators and potential targets in combating cancer drug resistance. Molecules. 2025;30(3):498.","journal-title":"Molecules"},{"key":"4137_CR166","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.cytogfr.2023.05.001","volume":"73","author":"B Pol\u00f3nia","year":"2023","unstructured":"Pol\u00f3nia B, Xavier CP, Kopecka J, Riganti C, Vasconcelos MH. The role of extracellular vesicles in glycolytic and lipid metabolic reprogramming of cancer cells: consequences for drug resistance. Cytokine Growth Factor Rev. 2023;73:150\u201362.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"11","key":"4137_CR167","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1038\/s41388-018-0557-9","volume":"38","author":"YB Hu","year":"2019","unstructured":"Hu YB, Yan C, Mu L, Mi YL, Zhao H, Hu H, et al. Exosomal Wnt-induced dedifferentiation of colorectal cancer cells contributes to chemotherapy resistance. Oncogene. 2019;38(11):1951\u201365.","journal-title":"Oncogene"},{"issue":"42","key":"4137_CR168","doi-asserted-by":"publisher","first-page":"2102220","DOI":"10.1002\/smll.202102220","volume":"17","author":"S Sharma","year":"2021","unstructured":"Sharma S, Masud MK, Kaneti YV, Rewatkar P, Koradia A, Hossain MS, et al. Extracellular vesicle nanoarchitectonics for novel drug delivery applications. Small. 2021;17(42):2102220. https:\/\/doi.org\/10.1002\/smll.202102220.","journal-title":"Small"},{"key":"4137_CR169","doi-asserted-by":"publisher","first-page":"1405267","DOI":"10.3389\/fonc.2024.1405267","volume":"14","author":"S Zakari","year":"2024","unstructured":"Zakari S, Niels NK, Olagunju GV, Nnaji PC, Ogunniyi O, Tebamifor M, et al. Emerging biomarkers for non-invasive diagnosis and treatment of cancer: a systematic review. Front Oncol. 2024;14:1405267.","journal-title":"Front Oncol"},{"issue":"6","key":"4137_CR170","doi-asserted-by":"publisher","first-page":"e006284","DOI":"10.1136\/jitc-2022-006284","volume":"11","author":"NP Semenkovich","year":"2023","unstructured":"Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. J Immunother Cancer. 2023;11(6):e006284.","journal-title":"J Immunother Cancer"},{"key":"4137_CR171","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/bs.mie.2019.07.018","volume":"636","author":"F Marliot","year":"2020","unstructured":"Marliot F, Lafontaine L, Galon J. Immunoscore assay for the immune classification of solid tumors: technical aspects, improvements and clinical perspectives. Methods Enzymol. 2020;636:109\u201328.","journal-title":"Methods Enzymol"},{"issue":"4","key":"4137_CR172","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3390\/pharmaceutics15041143","volume":"15","author":"SS Said","year":"2023","unstructured":"Said SS, Ibrahim WN. Cancer resistance to immunotherapy: comprehensive insights with future perspectives. Pharmaceutics. 2023;15(4):1143.","journal-title":"Pharmaceutics"},{"issue":"19","key":"4137_CR173","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, Hui R, Cs\u0151szi T, F\u00fcl\u00f6p A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823\u201333.","journal-title":"N Engl J Med"},{"key":"4137_CR174","doi-asserted-by":"publisher","first-page":"905520","DOI":"10.3389\/fonc.2022.905520","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Wen Q, Ding R. Therapeutic targeting of VEGF and\/or TGF-\u03b2 to enhance anti-PD-(L) 1 therapy: the evidence from clinical trials. Front Oncol. 2022;12:905520.","journal-title":"Front Oncol"},{"issue":"3","key":"4137_CR175","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40487-024-00287-2","volume":"12","author":"RD Gentzler","year":"2024","unstructured":"Gentzler RD, Guittar J, Mitra A, Iams WT, Driessen T, Schwind R, et al. Dynamic changes in circulating tumor fraction as a predictor of real-world clinical outcomes in solid tumor malignancy patients treated with immunotherapy. Oncol Ther. 2024;12(3):509\u201324. https:\/\/doi.org\/10.1007\/s40487-024-00287-2.","journal-title":"Oncol Ther"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04137-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04137-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04137-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:02:37Z","timestamp":1776769357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04137-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,22]]},"references-count":175,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4137"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04137-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,22]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript does not involve any human studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"None of the authors have any conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}